Latest From MaxCyte Inc.
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Large Molecule
- Synthesis Technologies, Production Processes
- Medical Devices
- Drug Delivery
- Therapeutic Areas
- TheraMed Inc.
- North America
- Parent & Subsidiaries
- MaxCyte Inc.
- Senior Management
Douglas A Doerfler, Pres. & CEO
Ronald Holtz, CFO
Deborah K Bowes, EVP, Bus. & Strategic Dev.
Madhusudan Peshwa, PhD, CSO, EVP, Cellular Therapies
Thomas M Ross, EVP, Global Sales
- Contact Info
Phone: (301) 944-1700
22 Firstfield Road
Gaithersburg, MD 20878